Ultragenyx Pharmaceutical Inc. (RARE) Shares Sold by Mutual of America Capital Management LLC
Mutual of America Capital Management LLC lowered its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 2.1% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 37,507 shares of the biopharmaceutical company’s stock after selling 813 shares during the quarter. Mutual of America Capital Management LLC owned 0.09% of Ultragenyx Pharmaceutical worth $2,330,000 as of its most recent filing with the SEC.
Other institutional investors have also added to or reduced their stakes in the company. Ameritas Investment Partners Inc. lifted its position in shares of Ultragenyx Pharmaceutical by 3.7% during the 1st quarter. Ameritas Investment Partners Inc. now owns 3,226 shares of the biopharmaceutical company’s stock valued at $219,000 after acquiring an additional 115 shares during the period. Prudential Financial Inc. grew its holdings in shares of Ultragenyx Pharmaceutical by 5.8% in the 1st quarter. Prudential Financial Inc. now owns 3,660 shares of the biopharmaceutical company’s stock worth $248,000 after acquiring an additional 200 shares during the period. Amalgamated Bank grew its holdings in shares of Ultragenyx Pharmaceutical by 4.6% in the 1st quarter. Amalgamated Bank now owns 4,628 shares of the biopharmaceutical company’s stock worth $314,000 after acquiring an additional 202 shares during the period. Tocqueville Asset Management L.P. grew its holdings in shares of Ultragenyx Pharmaceutical by 8.0% in the 2nd quarter. Tocqueville Asset Management L.P. now owns 3,375 shares of the biopharmaceutical company’s stock worth $210,000 after acquiring an additional 250 shares during the period. Finally, Aperio Group LLC grew its holdings in shares of Ultragenyx Pharmaceutical by 8.4% in the 2nd quarter. Aperio Group LLC now owns 3,851 shares of the biopharmaceutical company’s stock worth $239,000 after acquiring an additional 299 shares during the period. 96.07% of the stock is owned by institutional investors.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) opened at 57.32 on Tuesday. Ultragenyx Pharmaceutical Inc. has a 52-week low of $49.56 and a 52-week high of $91.35. The stock has a 50 day moving average of $54.16 and a 200-day moving average of $60.82. The firm’s market cap is $2.43 billion.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Thursday, July 27th. The biopharmaceutical company reported ($1.72) earnings per share for the quarter, topping the consensus estimate of ($1.73) by $0.01. During the same quarter in the previous year, the company earned ($1.46) earnings per share. On average, analysts expect that Ultragenyx Pharmaceutical Inc. will post ($7.14) EPS for the current year.
TRADEMARK VIOLATION WARNING: “Ultragenyx Pharmaceutical Inc. (RARE) Shares Sold by Mutual of America Capital Management LLC” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/10/03/ultragenyx-pharmaceutical-inc-rare-shares-sold-by-mutual-of-america-capital-management-llc.html.
Several equities analysts recently weighed in on RARE shares. Jefferies Group LLC reaffirmed a “hold” rating and issued a $68.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Friday, July 14th. BidaskClub upgraded Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Tuesday, June 20th. Stifel Nicolaus reiterated a “buy” rating and set a $85.00 target price (down from $95.00) on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, August 23rd. Cowen and Company reissued an “outperform” rating on shares of Ultragenyx Pharmaceutical in a report on Thursday, June 29th. Finally, JMP Securities lowered their target price on Ultragenyx Pharmaceutical from $90.00 to $80.00 and set a “market outperform” rating on the stock in a report on Wednesday, August 23rd. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and eight have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $71.65.
In other news, CEO Emil D. Kakkis acquired 7,500 shares of the firm’s stock in a transaction that occurred on Monday, August 28th. The stock was purchased at an average price of $52.52 per share, with a total value of $393,900.00. Following the purchase, the chief executive officer now owns 430,569 shares of the company’s stock, valued at approximately $22,613,483.88. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 9.20% of the stock is currently owned by corporate insiders.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.
Receive News & Stock Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.